Other Liabilities

Other liabilities comprised:

Other Liabilities

 

 

Dec. 31, 2015

 

Dec. 31, 2016

 

 

Total

 

Of which current

 

Total

 

Of which current

 

 

€ million

 

€ million

 

€ million

 

€ million

Other tax liabilities

 

435

 

428

 

544

 

527

Deferred income

 

1,148

 

204

 

1,463

 

651

Liabilities to employees

 

217

 

210

 

229

 

219

Liabilities for social expenses

 

174

 

165

 

168

 

157

Accrued interest on liabilities

 

189

 

180

 

186

 

181

Miscellaneous liabilities

 

436

 

347

 

788

 

686

Total

 

2,599

 

1,534

 

3,378

 

2,421

Deferred income included an upfront payment, originally amounting to US$1 billion, in connection with the strategic pharmaceutical collaboration agreed between Bayer and Merck & Co., Inc., United States, in the field of soluble guanylate cyclase (sGC) modulation. This deferred income is being amortized over a period of 13.5 years as the obligations are satisfied. The remaining amount deferred at the end of 2016 was €660 million (2015: €719 million). The amount amortized in 2016 was €59 million (2015: €59 million).

Deferred income also included the proceeds from the sale of the Diabetes Care business at the beginning of 2016. The original sale proceeds of around €1 billion are being realized over a period of up to 24 months as the obligations are satisfied. €469 million remained deferred at the end of 2016.

The deferred income included €62 million (2015: €62 million) in grants and subsidies received from governments, of which €15 million (2015: €7 million) was reversed and recognized in profit or loss.

The miscellaneous liabilities included €271 million (2015: €125 million) from derivatives.